Celgene Corporation (CELG)
CELG (NASDAQ:Drugs)
$123.50
+0.38
+0.31%
Today's Range: 122.41 - 124.37 |
CELG Avg Daily Volume: 3,282,800
| Last Update: 05/21/13 - 4:00 PM EDT |
| Volume: 2,401,866 |
| YTD Performance: 59.18%
|
| Open: $123.24 |
| Previous Close: $123.12 |
| 52 Week Range: $58.53 -
$131.82 |
| Oustanding Shares: 417,122,477 |
| Market Cap: 52,102,768,602 |
6-Month Chart
TheStreet Ratings Grade for CELG
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
19 |
21 |
21 |
21 |
| Moderate Buy |
2 |
2 |
2 |
2 |
| Hold |
4 |
3 |
4 |
4 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.40 |
1.29 |
1.35 |
1.35 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
02/27/06 |
| Price Earnings Ratio: |
37.97 |
|
| Price Earnings Comparisons: |
| CELG |
Sector Avg. |
S&P 500 |
| 37.97 |
38.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
26.47%
|
78.25%
|
109.02%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
13.70 |
1.05 |
0.27 |
| Net Income |
10.50 |
0.87 |
0.23 |
| EPS |
15.80 |
1.00 |
0.26 |
| Earnings for CELG: |
| EBITDA |
2.20B |
| Revenue |
5.51B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.31 |
$1.29 |
$5.21 |
$6.36 |
| Number of Analysts |
4 |
4 |
4 |
4 |
| High Estimate |
$1.36 |
$1.37 |
$5.46 |
$7.09 |
| Low Estimate |
$1.25 |
$1.26 |
$5.08 |
$5.91 |
| Prior Year |
$1.12 |
$1.19 |
$4.50 |
$5.21 |
| Growth Rate (Year over Year) |
16.74% |
8.61% |
15.78% |
22.12% |
| May 10, 2013 | 12:52 PM EDT
Just a natural change in leadership.
| May 03, 2013 | 7:23 AM EDT
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.
| Apr 24, 2013 | 6:50 PM EDT
Banks continued higher, basic materials outperformed.
| Apr 24, 2013 | 1:16 PM EDT
It’s the only thing that explains today’s action.
| Apr 22, 2013 | 11:00 AM EDT
Beware of cramming all your funds in one basket.
| Apr 17, 2013 | 6:20 AM EDT
These four names in particular have made some stunning moves.
| Apr 15, 2013 | 7:43 AM EDT
Keep that in mind as the market reacts to China this morning.
| Apr 11, 2013 | 10:24 AM EDT
Plenty of leadership remains in the health care sector and there’s reason to see further potential.
| Apr 10, 2013 | 3:32 PM EDT
Deep-in-the-money call options on these five names could provide a healthy return.
| Apr 02, 2013 | 3:00 PM EDT
If you're overly cautious about biotech, you could incur some major opportunity costs.
